The invention provides stable aqueous pharmaceutical formulations comprising the therapeutic antibody, bevacizumab, in an amount of 45-55mg/mL, trehalose in an amount of 50-70mM, a sodium phosphate buffer in an amount of 22-28mM, polysorbate 20 in a concentration of 0.01% to 0.1% and having a pH in the range of about 5.5 to about 7.0. The invention also provides methods for making such formulations and methods of using such formulations. In the past years, advances in biotechnology have made it possible to produce a variety of proteins for pharmaceutical applications using recombinant DNA techniques.
